Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.3.1039

Prospective Study on the Survival of HCC Patients Treated with Transcatheter Arterial Lipiodol Chemoembolization  

Mao, Ying-Min (Department of Radiology, Zhejiang Provincial People's Hospital)
Luo, Zu-Yan (Department of Radiology, Zhejiang Provincial People's Hospital)
Li, Bo (Department of Radiology, Zhejiang Provincial People's Hospital)
Hu, Ting-Yang (Department of Radiology, Zhejiang Provincial People's Hospital)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.3, 2012 , pp. 1039-1042 More about this Journal
Abstract
Aim: Tanscatheter arterial embolization irrespective of with or without an anticancer agent and lipiodol has been controversial with regard to survival benefit. Therefore, we conducted a prospective study to analyze the effect of transcatheter arterial lipiodol chemoembolization (TACE) on the survival of HCC. Methods: A prospective study was conducted, and a total of 326 patients with primary liver cancer who were newly diagnosed were collected from January 2004 to January 2005 in Zhejiang Provincial People's Hospital of China. A univariate Cox's regression analysis was used to assess the survival of the HCC cases receiving TACE. Results: The duration of follow-up for the HCC patients treated with TACE ranged from 3 months to 60 months. For the overall patients, survival rate at 5 years was 42%. Both HBV Ag and HCV Ab positive patients showed significantly low survival rate at 5 years. The multivariate analysis revealed The IV TNM stage was related to an heavy increased risk of death of HCC patients, and Child C grade group showed a significant moderate increased risk. Conclusion: Our study showed TACE is associated with a better prognosis of HCC patients, and the HBV infection, TNM stage, Child-Pugh grade and number of TACE may influence the survival probability. Further TACE studies should be assess the quality of life of HCC patients, so as to provide more information for treatment of HCC.
Keywords
TACE; survival; HCC; China;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Nakamura H, Tanaka T, Hori S, et al (1983). Transcatheter embolization of hepatocellular carcinoma: assessment of efficacy in cases of resection following embolization. Radiology, 147, 401-5.   DOI
2 Okuda K, Obata H, Ohtsuki T, et al (1984). Prognosis of primary hepatocellular carcinoma. Hepatology, 4, S3-6.   DOI
3 Raoul JL, Hersebach D, Bretagne JF, et al (1992). Chemoembolization of hepatocellular carcinomas: a study of the biodistribution and pharmokinetics of doxorubicin. Cancer, 70, 585-90.   DOI   ScienceOn
4 Savastano S, Miotto D, Casarrubea G, et al (1999). Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child's grade A or B cirrhosis: a multivariate analysis of prognostic factors. J Clin Gastroenterol, 28, 334-40.   DOI
5 Solomon B, Soulen MC, Baum RA, et al (1999). Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a US population. J Vasc Interv Radiol, 10, 793-8.   DOI
6 Bruix J, Castells A,Montanya X, et al (1994). Phase II study of transarterial embolisation in European patients with hepatocellular carcinoma: need for controlled trials. Hepatology, 20, 643-50.   DOI   ScienceOn
7 Doyon DMA, Jourde AM, Regensberg C, et al (1974). L'embolisation arterielle hepatique dans les tumeurs malignes du foie. Ann Radiol, 17, 593-603.
8 Chen MF, Hwang TL, Jeng LB, et al (1994). Postoperative recurrence of hepatocellular carcinoma. Two hundred five consecutive patients who underwent hepatic resection in 15 years. Arch Surg, 129, 738-42.   DOI
9 Chin PL, Chu DZJ, Clarke KG, et al (1999). Ethnic differences in the behavior of hepatocellular carcinoma. Cancer, 85, 1931-6.   DOI
10 Choi BI, Kim HC, Han JK, et al (1992). Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma: CT and pathological findings. Radiology, 182, 709-13.   DOI
11 Farinati F, De Maria N, Marafin C, et al (1996). Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization. Dig Dis Sci, 41, 2332-9.   DOI
12 Huppert PE, Geissier F, Duda SH, et al (1994). Chemoembolisation deshepatozellularen karzinom: computertomographische befunde unf klinische resultate bei prospektiv repetitiver therapie. Rofo Forschr Geb Rontgenstr Neuen Bildgeb Verfahr, 160, 425-32.   DOI
13 Ikeda K, Kumada H, Saitoh S, et al (1991). Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma: an analysis by the Cox proportional hazard model. Cancer, 68, 2150-4.   DOI   ScienceOn
14 Imamura H, Matsuyama Y, Tanaka E, et al (2003). Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol, 38, 200-7.
15 Llovet JM, Burroughs A, Bruix J (2003). Hepatocellular carcinoma. Lancet, 362, 1907-17.   DOI   ScienceOn
16 Koda M, Murawaki Y, Mitsuda A, et al (2000). Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma. Cancer, 88, 529-37.   DOI   ScienceOn
17 Konno T, Maeda H, Iwai K, et al (1983). Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol, 19, 1053-65.   DOI
18 Lee HS, Kim KM, Yoon JH, et al (2002). Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J Clin Oncol, 20, 4459-65.   DOI   ScienceOn
19 Llovet JM, Real MI, Montana X, et al (2002). Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet, 359, 1734-9.   DOI
20 Lo CM, Ngan H, Tso WK, et al (2002). Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology, 35, 1164-71.   DOI   ScienceOn
21 Lopez RR, Pan SH, Hoffman L, et al (2002). Comparison of transarterial chemoembolization in patients with unresectable diffuse vs. focal hepatocellular carcinoma. Arch Surg, 137, 653-8.   DOI
22 Mondazzi L, Bottelli R, Brambilla G, et al (1994). Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology, 19, 1115-23.   DOI